Literature DB >> 22407175

Assessment of intra-observer variability in measurement of high-grade brain tumors.

James M Provenzale1, Michael C Mancini.   

Abstract

A 25% increase in bidimensional products (BPs) of tumor diameter has been used as a criterion for brain tumor progression. We studied intra-observer variability in measurements of BPs. Ten patients with contrast-enhancing glioblastoma multiforme underwent baseline and follow-up MR imaging. Seven observers measured BPs in various planes. Differences in BPs between scans were expressed as a percentage of baseline. This calculation was performed for both readings of the baseline and follow-up scans. Differences between change from baseline to follow-up on each reading (termed D values) were calculated for each reader (total of 196 D values). Median D value in each plane was calculated for each reader. Range of D values was 12.36-33.64% in axial plane (average 10.63%), 12.18-38.62% in coronal plane (average 26.84%) and 15.12-35.48% in sagittal plane (average 26.11%). Across all planes, 88 (45%) D values were >25%. When all imaging planes for any single observation were combined, in 76% of cases, at least one D value of >25% was seen. Based on the high degree of intra-observer variability, tumor measurements producing an increase in BP of >25% can routinely be obtained solely by chance.

Entities:  

Mesh:

Year:  2012        PMID: 22407175     DOI: 10.1007/s11060-012-0843-2

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  12 in total

1.  Comparison of diameter and perimeter methods for tumor volume calculation.

Authors:  A G Sorensen; S Patel; C Harmath; S Bridges; J Synnott; A Sievers; Y H Yoon; E J Lee; M C Yang; R F Lewis; G J Harris; M Lev; P W Schaefer; B R Buchbinder; G Barest; K Yamada; J Ponzo; H Y Kwon; J Gemmete; J Farkas; A L Tievsky; R B Ziegler; M R Salhus; R Weisskoff
Journal:  J Clin Oncol       Date:  2001-01-15       Impact factor: 44.544

2.  Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.

Authors:  Patrick Y Wen; David R Macdonald; David A Reardon; Timothy F Cloughesy; A Gregory Sorensen; Evanthia Galanis; John Degroot; Wolfgang Wick; Mark R Gilbert; Andrew B Lassman; Christina Tsien; Tom Mikkelsen; Eric T Wong; Marc C Chamberlain; Roger Stupp; Kathleen R Lamborn; Michael A Vogelbaum; Martin J van den Bent; Susan M Chang
Journal:  J Clin Oncol       Date:  2010-03-15       Impact factor: 44.544

3.  Response criteria for phase II studies of supratentorial malignant glioma.

Authors:  D R Macdonald; T L Cascino; S C Schold; J G Cairncross
Journal:  J Clin Oncol       Date:  1990-07       Impact factor: 44.544

4.  Interobserver variations in gross tumor volume delineation of brain tumors on computed tomography and impact of magnetic resonance imaging.

Authors:  C Weltens; J Menten; M Feron; E Bellon; P Demaerel; F Maes; W Van den Bogaert; E van der Schueren
Journal:  Radiother Oncol       Date:  2001-07       Impact factor: 6.280

5.  Intra- and interobserver variability of linear and volumetric measurements of brain metastases using contrast-enhanced magnetic resonance imaging.

Authors:  Hans-Christian Bauknecht; Valentina C Romano; Patrik Rogalla; Randolf Klingebiel; Claudia Wolf; Lars Bornemann; Bernd Hamm; Patrick A Hein
Journal:  Invest Radiol       Date:  2010-01       Impact factor: 6.016

Review 6.  Response assessment challenges in clinical trials of gliomas.

Authors:  Patrick Y Wen; Andrew D Norden; Jan Drappatz; Eudocia Quant
Journal:  Curr Oncol Rep       Date:  2010-01       Impact factor: 5.075

Review 7.  Clinical trial end points for high-grade glioma: the evolving landscape.

Authors:  David A Reardon; Evanthia Galanis; John F DeGroot; Timothy F Cloughesy; Jeffrey S Wefel; Kathleen R Lamborn; Andrew B Lassman; Mark R Gilbert; John H Sampson; Wolfgang Wick; Marc C Chamberlain; David R Macdonald; Minesh P Mehta; Michael A Vogelbaum; Susan M Chang; Martin J Van den Bent; Patrick Y Wen
Journal:  Neuro Oncol       Date:  2011-02-09       Impact factor: 12.300

8.  Bidimensional measurements in brain tumors: assessment of interobserver variability.

Authors:  James M Provenzale; Claro Ison; David Delong
Journal:  AJR Am J Roentgenol       Date:  2009-12       Impact factor: 3.959

9.  Inter-observer variability in the measurement of diffuse intrinsic pontine gliomas.

Authors:  Robert M Hayward; Nicolas Patronas; Eva H Baker; Gilbert Vézina; Paul S Albert; Katherine E Warren
Journal:  J Neurooncol       Date:  2008-06-28       Impact factor: 4.130

10.  Quality assessment of medical decision making in radiation oncology: variability in target volume delineation for brain tumours.

Authors:  G Leunens; J Menten; C Weltens; J Verstraete; E van der Schueren
Journal:  Radiother Oncol       Date:  1993-11       Impact factor: 6.280

View more
  14 in total

1.  Volumetric analysis of IDH-mutant lower-grade glioma: a natural history study of tumor growth rates before and after treatment.

Authors:  Raymond Y Huang; Robert J Young; Benjamin M Ellingson; Harini Veeraraghavan; Wei Wang; Florent Tixier; Hyemin Um; Rasheed Nawaz; Tracy Luks; John Kim; Elizabeth R Gerstner; David Schiff; Katherine B Peters; Ingo K Mellinghoff; Susan M Chang; Timothy F Cloughesy; Patrick Y Wen
Journal:  Neuro Oncol       Date:  2020-12-18       Impact factor: 12.300

2.  Response assessment in high-grade glioma: tumor volume as endpoint.

Authors:  Raymond Huang
Journal:  Neuro Oncol       Date:  2017-06-01       Impact factor: 12.300

3.  Small increases in enhancement on MRI may predict survival post radiotherapy in patients with glioblastoma.

Authors:  Cecelia Elizabeth Gzell; Helen R Wheeler; Philip McCloud; Marina Kastelan; Michael Back
Journal:  J Neurooncol       Date:  2016-02-15       Impact factor: 4.130

4.  A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K.

Authors:  Daniel J Ma; Evanthia Galanis; S Keith Anderson; David Schiff; Timothy J Kaufmann; Patrick J Peller; Caterina Giannini; Paul D Brown; Joon H Uhm; Steven McGraw; Kurt A Jaeckle; Patrick J Flynn; Keith L Ligon; Jan C Buckner; Jann N Sarkaria
Journal:  Neuro Oncol       Date:  2014-12-18       Impact factor: 12.300

Review 5.  Standard of care and future pharmacological treatment options for malignant glioma: an urgent need for screening and identification of novel tumor-specific antigens.

Authors:  Kristen A Batich; John H Sampson
Journal:  Expert Opin Pharmacother       Date:  2014-08-19       Impact factor: 3.889

Review 6.  How Machine Learning is Powering Neuroimaging to Improve Brain Health.

Authors:  Nalini M Singh; Jordan B Harrod; Sandya Subramanian; Mitchell Robinson; Ken Chang; Suheyla Cetin-Karayumak; Adrian Vasile Dalca; Simon Eickhoff; Michael Fox; Loraine Franke; Polina Golland; Daniel Haehn; Juan Eugenio Iglesias; Lauren J O'Donnell; Yangming Ou; Yogesh Rathi; Shan H Siddiqi; Haoqi Sun; M Brandon Westover; Susan Whitfield-Gabrieli; Randy L Gollub
Journal:  Neuroinformatics       Date:  2022-03-28

Review 7.  Treatment-related changes in glioblastoma: a review on the controversies in response assessment criteria and the concepts of true progression, pseudoprogression, pseudoresponse and radionecrosis.

Authors:  P D Delgado-López; E Riñones-Mena; E M Corrales-García
Journal:  Clin Transl Oncol       Date:  2017-12-07       Impact factor: 3.405

8.  Semiautomated volumetric measurement on postcontrast MR imaging for analysis of recurrent and residual disease in glioblastoma multiforme.

Authors:  D S Chow; J Qi; X Guo; V Z Miloushev; F M Iwamoto; J N Bruce; A B Lassman; L H Schwartz; A Lignelli; B Zhao; C G Filippi
Journal:  AJNR Am J Neuroradiol       Date:  2013-08-29       Impact factor: 3.825

9.  Prognostic value and kinetics of circulating endothelial cells in patients with recurrent glioblastoma randomised to bevacizumab plus lomustine, bevacizumab single agent or lomustine single agent. A report from the Dutch Neuro-Oncology Group BELOB trial.

Authors:  N Beije; J Kraan; W Taal; B van der Holt; H M Oosterkamp; A M Walenkamp; L Beerepoot; M Hanse; M E van Linde; A Otten; R M Vernhout; F Y F de Vos; J W Gratama; S Sleijfer; M J van den Bent
Journal:  Br J Cancer       Date:  2015-06-04       Impact factor: 7.640

Review 10.  Response assessment criteria for glioblastoma: practical adaptation and implementation in clinical trials of antiangiogenic therapy.

Authors:  Olivier L Chinot; David R Macdonald; Lauren E Abrey; Gudrun Zahlmann; Yannick Kerloëguen; Timothy F Cloughesy
Journal:  Curr Neurol Neurosci Rep       Date:  2013-05       Impact factor: 5.081

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.